Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul;7(7):547-558.
Epub 2019 Jun 21.

Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics

Affiliations

Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics

Willam T Wang et al. EC Pharmacol Toxicol. 2019 Jul.

Abstract

Alzheimer's disease (AD) characterized by insoluble amyloid-β (Aβ) deposits, neurofibrillary tangles (NFTs), and neuronal demise. The influence of environmental and genetic factors on AD progression remains elusive, however evidence suggests biometal dyshomeostasis elicits neuronal death, neuroinflammation, and accumulated oxidative damages in AD brain. As such, three pathways have been identified that result from abnormal biometal accumulation and increased levels of reactive oxygen species (ROS) and reactive nitrogen species (RNS) in AD brain parenchyma: (1) the damage caused by direct oxidation of cellular components such as DNA and proteins; (2) the oligomerization of Aβ and NFTs, and (3) the promotion of apoptosis through NF-κB signaling pathway. Finally, given recent developments in nanotechnology, we have briefly reviewed potential nanotheranostic agents as potential AD theranostics.

Keywords: Alzheimer’s Disease; Aβ Amyloid; Biometals; Blood-Brain Barrier; Metal Chelators; Nanotheranostics; Redox Stress; Tau Protein.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest The authors declare no conflict of interest.

Similar articles

Cited by

References

    1. Alzheimer’s A.“Alzheimer’s disease facts and figures”. Alzheimer’s and Dementia 124 (2016): 459–509. - PubMed
    1. Wilson RS, et al. “The natural history of cognitive decline in Alzheimer’s disease”. Psychology and Aging 274 (2012): 1008–1017. - PMC - PubMed
    1. Bekris LM, et al. “Genetics of Alzheimer disease”. Journal of Geriatric Psychiatry and Neurology 23 (2010): 213–227. - PMC - PubMed
    1. Bateman RJ, et al. “Clinical and biomarker changes in dominantly inherited Alzheimer’s disease”. New England Journal of Medicine 367 (2012): 795–804. - PMC - PubMed
    1. Karch CM, et al. “Alzheimer’s disease genetics: from the bench to the clinic”. Neuron 831 (2014): 11–26. - PMC - PubMed

LinkOut - more resources